The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions.
Continue ReadingAs part of our rapidly expanding efforts to secure a clear path for the development of treatments and funding for celiac disease at the federal level, we are pleased to…
Continue ReadingThe Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).
Continue ReadingWe are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country
Continue ReadingImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…
Continue ReadingI cannot stress enough how important your generous commitment is to our ongoing work here at Celiac Disease Foundation. I am pleased to report that we are making real progress…
Continue ReadingCurrently, the typical treatment for a patient diagnosed with celiac disease is a strict gluten-free diet for life. Future therapies currently in the pipeline hope to make living with celiac disease less of a burden.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...